Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Denali Therapeutics (DNLI) Operating Expenses: 2016-2024

Historic Operating Expenses for Denali Therapeutics (DNLI) over the last 9 years, with Dec 2024 value amounting to $501.9 million.

  • Denali Therapeutics' Operating Expenses fell 2.06% to $129.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $501.9 million, marking a year-over-year decrease of 4.81%. This contributed to the annual value of $501.9 million for FY2024, which is 4.81% down from last year.
  • Denali Therapeutics' Operating Expenses amounted to $501.9 million in FY2024, which was down 4.81% from $527.2 million recorded in FY2023.
  • Over the past 5 years, Denali Therapeutics' Operating Expenses peaked at $527.2 million during FY2023, and registered a low of $272.9 million during FY2020.
  • Moreover, its 3-year median value for Operating Expenses was $501.9 million (2024), whereas its average is $492.8 million.
  • Per our database at Business Quant, Denali Therapeutics' Operating Expenses skyrocketed by 30.43% in 2022 and then declined by 4.81% in 2024.
  • Over the past 5 years, Denali Therapeutics' Operating Expenses (Yearly) stood at $272.9 million in 2020, then rose by 26.19% to $344.4 million in 2021, then surged by 30.43% to $449.2 million in 2022, then grew by 17.37% to $527.2 million in 2023, then declined by 4.81% to $501.9 million in 2024.